Will Cabazitaxel Success Derail Other Prostate Cancer Trials?
This article was originally published in The Pink Sheet Daily
Executive Summary
Rival Medivation has a "Plan B" for Phase III if Sanofi-Aventis' cabazitaxel emerges as new standard of care as expected.